GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Enterprise Value
中文

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Enterprise Value : $-3.49 Mil (As of Apr. 24, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fresh Tracks Therapeutics's Enterprise Value is $-3.49 Mil. Fresh Tracks Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.69 Mil. Therefore, Fresh Tracks Therapeutics's EV-to-EBIT ratio for today is 0.61.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Fresh Tracks Therapeutics's Enterprise Value is $-3.49 Mil. Fresh Tracks Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.65 Mil. Therefore, Fresh Tracks Therapeutics's EV-to-EBITDA ratio for today is 0.62.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Fresh Tracks Therapeutics's Enterprise Value is $-3.49 Mil. Fresh Tracks Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $8.01 Mil. Therefore, Fresh Tracks Therapeutics's EV-to-Revenue ratio for today is -0.44.


Fresh Tracks Therapeutics Enterprise Value Historical Data

The historical data trend for Fresh Tracks Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Enterprise Value Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 12.19 0.51 -4.10 -5.62

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.10 -6.84 -4.79 -6.27 -5.62

Competitive Comparison of Fresh Tracks Therapeutics's Enterprise Value

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Enterprise Value falls into.



Fresh Tracks Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Fresh Tracks Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Fresh Tracks Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh Tracks Therapeutics  (OTCPK:FRTX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Fresh Tracks Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-3.493/-5.689
=0.61

Fresh Tracks Therapeutics's current Enterprise Value is $-3.49 Mil.
Fresh Tracks Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.69 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Fresh Tracks Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-3.493/-5.648
=0.62

Fresh Tracks Therapeutics's current Enterprise Value is $-3.49 Mil.
Fresh Tracks Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.65 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Fresh Tracks Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-3.493/8.006
=-0.44

Fresh Tracks Therapeutics's current Enterprise Value is $-3.49 Mil.
Fresh Tracks Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh Tracks Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301